Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Temsirolimus, a novel inhibitor of MTOR, studied
September 14th, 2005
Temsirolimus, a novel inhibitor of mammalian target of rapamycin (mTOR), was studied. According to a study from the United Kingdom, "In this study, two doses of temsirolimus (CCI-779), a novel inhibitor of the mTOR, were evaluated for efficacy, safety, and pharmacokinetics in patients with locally advanced or metastatic breast cancer who had been heavily pretreated. Patients (n=109) were randomly assigned to receive 75 or 250 mg of temsirolimus weekly as a 30-minute intravenous infusion. Patients were evaluated for tumor response, time to tumor progression, adverse events, and pharmacokinetics of temsirolimus." "Temsirolimus produced an objective...
Source: Vaccine Weekly (2005-09-14)
|
